Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $1.3 million.

  • Lyell Immunopharma's Cash from Financing Activities was N/A to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.6 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is 23.92% down from last year.
  • Lyell Immunopharma's Cash from Financing Activities amounted to $1.3 million in FY2024, which was down 23.92% from $1.7 million recorded in FY2023.
  • Lyell Immunopharma's 5-year Cash from Financing Activities high stood at $476.8 million for FY2020, and its period low was $1.3 million during FY2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $1.7 million (2023), whereas its average is $4.6 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Cash from Financing Activities spiked by 35.78% in 2020, and later tumbled by 97.35% in 2022.
  • Over the past 5 years, Lyell Immunopharma's Cash from Financing Activities (Yearly) stood at $476.8 million in 2020, then declined by 15.84% to $401.2 million in 2021, then slumped by 97.35% to $10.6 million in 2022, then crashed by 83.61% to $1.7 million in 2023, then dropped by 23.92% to $1.3 million in 2024.